Dawn Lee

Summary

Publications

  1. doi Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma
    D Lee
    BresMed, North Church House, 84 Queen Street, Sheffield, S1 2DW, UK
    BioDrugs 30:307-19. 2016
  2. doi Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer
    Dawn Lee
    BresMed, Sheffield, United Kingdom Electronic address
    J Urol 193:839-46. 2015
  3. pmc Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland
    Dawn Lee
    BresMed, North Church House, 84 Queen Street, Sheffield, S1 2DW, UK
    Appl Health Econ Health Policy 11:457-69. 2013
  4. doi The cost effectiveness of licensed oromucosal midazolam (Buccolam(®)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited
    Dawn Lee
    BresMed, North Church House, 84 Queen Street, Sheffield, S1 2DW, UK
    Paediatr Drugs 15:151-62. 2013
  5. doi The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight
    Anthony J Hatswell
    BresMed, Sheffield, South Yorkshire, UK University College London, London, UK Electronic address
    Value Health 19:1055-1058. 2016
  6. doi A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom
    Dawn Lee
    Bsc, BresMed, Sheffield, UK
    J Med Econ 17:233-47. 2014

Collaborators

Detail Information

Publications6

  1. doi Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma
    D Lee
    BresMed, North Church House, 84 Queen Street, Sheffield, S1 2DW, UK
    BioDrugs 30:307-19. 2016
    ..Newer techniques that compare treatments where the proportional hazards assumption is violated and adjust for use of subsequent therapies often require patient-level data, which are rarely available for all treatments...
  2. doi Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer
    Dawn Lee
    BresMed, Sheffield, United Kingdom Electronic address
    J Urol 193:839-46. 2015
    ....
  3. pmc Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland
    Dawn Lee
    BresMed, North Church House, 84 Queen Street, Sheffield, S1 2DW, UK
    Appl Health Econ Health Policy 11:457-69. 2013
    ..Clinical trials have shown that romiplostim increases platelet counts, while reducing the risk of bleeding and, in turn, the need for costly rescue medications...
  4. doi The cost effectiveness of licensed oromucosal midazolam (Buccolam(®)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited
    Dawn Lee
    BresMed, North Church House, 84 Queen Street, Sheffield, S1 2DW, UK
    Paediatr Drugs 15:151-62. 2013
    ..This can lead to challenges when conducting economic evaluations...
  5. doi The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight
    Anthony J Hatswell
    BresMed, Sheffield, South Yorkshire, UK University College London, London, UK Electronic address
    Value Health 19:1055-1058. 2016
    ....
  6. doi A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom
    Dawn Lee
    Bsc, BresMed, Sheffield, UK
    J Med Econ 17:233-47. 2014
    ....